Tag

Glp 1s

All articles tagged with #glp 1s

health19 hours ago•3 min saved

GLP-1 Weight Drugs: Debunking the 'bones-shredding' myth

A viral claim that GLP-1 drugs like semaglutide (Ozempic) shred bones isn’t supported. A preliminary AAOS presentation linked GLP-1 use with higher rates of osteoporosis and osteomalacia, but the absolute numbers were small (about 4% and 2%), and weight loss itself may drive risk. Doctors advise monitoring bone health and preventive steps (calcium, vitamin D, strength training). Another study at the same conference suggested GLP-1s could reduce some postoperative complications in orthopedic patients. GLP-1s have GI side effects and potential eye risks, but their overall benefits for obesity and diabetes remain substantial; the key is weighing benefits against risks with a clinician and avoiding sensational myths.

via Gizmodo|

#bone-health #glp-1s #health

health23 days ago•4 min saved

Heart Risk Surges Within Months of Quitting GLP-1 Diabetes Drugs

A large VA study found that staying on GLP-1 medications (such as semaglutide) for at least two years lowers major cardiovascular events by about 18% versus controls, but stopping the therapy leads to a rapid rebound in risk within six months—worsened by cost, side effects, and access barriers—highlighting the need for long-term maintenance and affordable access to these drugs.

via Gizmodo|

#cardiovascular-disease #glp-1s #health

business1 month ago•4 min saved

Weight-Loss Giants End War as Hims Sells Ozempic and Wegovy at Discount

Novo Nordisk and Hims ended their dispute and formed a partnership in which Hims will sell Ozempic and Wegovy at Novo’s price, while Novo Nordisk dropped its lawsuit; the deal aims to curb compounded GLP-1 copycats and ease access as FDA scrutiny and price reductions reshape the market, though affordability and access remain uneven for many patients.

via Gizmodo|

#business #glp-1s #novo-nordisk

business2 months ago•2 min saved

Lilly Surges on GLP-1 Demand, Sets 2026 Revenue Outlook

Eli Lilly beat Q4 estimates with adjusted EPS of $7.54 and revenue of $19.29B (up 43%), and issued 2026 guidance of $80-83B in revenue and $33.50-35 in EPS, powered by robust GLP-1 demand for Zepbound and Mounjaro. U.S. sales reached $12.9B with volume up about 50% while prices moderated. Lilly faces competition from Novo Nordisk and highlighted pricing steps under a 2026 deal with Medicare/Medicaid and a direct-to-consumer TrumpRx platform, with most pricing moves expected early in 2026 and volume growth ramping in the second half. The company is also pursuing an oral weight-loss drug, orforglipron, later this year.

via CNBC|

#business #earnings #eli-lilly

business8 months ago•2 min saved

Linda Yaccarino Becomes CEO of Telehealth Firm eMed After Leaving X

Linda Yaccarino, former CEO of X, has been appointed as the CEO of eMed Population Health, an AI startup focusing on health technology related to GLP-1 drugs for weight management and diabetes, leveraging her negotiation skills and tech industry recognition to lead the company's efforts to improve global healthcare outcomes.

via TechCrunch|

#business #ceo #emed

health-medicine2 years ago•10 min saved

"The Evolution of Weight-Loss Medications: From Fen-Phen to Ozempic and Beyond"

The rise of weight-loss drugs like Ozempic has drawn comparisons to the infamous fen-phen, but there are key differences. While fen-phen was a combination of appetite suppressants linked to severe heart problems, newer drugs like semaglutide and tirzepatide work differently as part of the incretin class, mimicking hormones to regulate hunger and metabolism. Large-scale clinical trials have shown that these drugs help obese people lose substantial weight and reduce the risk of heart and kidney problems, but they also come with potential side effects and supply issues. The lesson from the fen-phen crisis is that every approved medical treatment has its risks, and it's crucial for doctors, regulators, and the public to weigh the benefits against the potential risks.

via Gizmodo|

#fen-phen #glp-1s #health-medicine

health-and-wellness2 years ago•4 min saved

"Survey Reveals High Costs Driving Demand for Weight-Loss Drugs"

A recent survey by Evercore ISI reveals that demand for weight loss drugs, particularly GLP-1s, is high in the U.S. despite limited insurance coverage and monthly costs ranging from $900 to $1,350. The survey indicates that willingness to pay for these drugs is strongly correlated with annual income, with higher-income individuals willing to pay more out of pocket. Concerns about equity in access to these drugs arise due to disparities in out-of-pocket costs. Additionally, the survey highlights that many patients stop taking the drugs prematurely due to cost or achieving weight loss goals, but a significant portion intend to stay on the drugs permanently. Furthermore, the drugs have been observed to affect eating and drinking habits, with most respondents reporting eating less and drinking less alcohol while on the medication.

via CNBC|

#glp-1s #health-and-wellness #out-of-pocket-costs

health2 years ago•6 min saved

"Breakthrough Liver Disease Drug Marks New Era in Biopharma Innovation"

The FDA has approved Madrigal Pharmaceuticals' drug "Rezdiffra" for the treatment of nonalcoholic steatohepatitis (NASH), a common and serious liver disease affecting millions of Americans. The approval marks a significant milestone as it is the first-ever treatment for NASH, with a price tag of $47,400 per year. This decision opens the door for other companies developing NASH treatments, and several biotech firms are currently studying experimental drugs for the condition. Additionally, the use of GLP-1s, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, in treating NASH is being closely watched, as they could potentially dominate the market. The approval of Rezdiffra without the need for a liver biopsy could accelerate and broaden patient access to NASH treatments.

via CNBC|

#fda-approval #glp-1s #health

health2 years ago•6 min saved

"Exploring the Link Between Weight Loss Drugs and Mental Health Benefits"

The complex relationship between weight loss drugs, particularly GLP-1s, and mental health is a topic of concern for endocrinologists and psychiatrists. While these drugs have shown effectiveness in treating obesity, their impact on mental health remains unclear. Some reports suggest a potential link between GLP-1s and suicidal thoughts, but emerging data also indicates neuroprotective effects, especially in depression and cognitive function. Close collaboration between doctors treating the body and those treating the mind is crucial, as patients with mental health disorders often face challenges with weight-promoting psychiatric medications. Despite the need for further research, there is evidence that GLP-1s may simultaneously treat depressive symptoms and improve quality of life for patients with obesity and mental illness.

via STAT|

#glp-1s #health #mental-health

health-and-wellness2 years ago•1 min saved

"Weight-loss Medications' Impact on Consumer Spending and Industry Adaptation"

A survey by Morgan Stanley indicates that households with members using major weight-loss drugs like GLP-1s are spending less on groceries, with a 6% to 9% decrease in monthly grocery spending compared to non-users. The most negatively impacted categories for spending include snacks, pastries, and ice cream, while yogurt, fish, and vegetable snacks are positively impacted. This trend is attributed to reduced consumption of less healthy categories when taking GLP-1 drugs, leading to decreased grocery bills for these households.

via Seeking Alpha|

#eli-lilly #glp-1s #grocery-spending

health2 years ago•6 min saved

"Unveiling the Truth About Weight Loss Drugs: What You Need to Know"

New weight loss drugs, known as GLP-1 receptor agonists, are making weight loss more effortless by quieting brain chatter about food. These drugs, such as semaglutide and tirzepatide, are approved to treat people with obesity and type 2 diabetes, and have shown to be effective in helping many people lose weight. They have a relatively long track record for safety, but require close follow-up and are just one component of a comprehensive plan to treat obesity.

via CNN|

#glp-1s #health #obesity-treatment

businesshealthcare2 years ago•4 min saved

"The Decline of Wall Street's Concern Over Weight Loss Drug Craze Impact"

Wall Street's fears of weight loss drugs impacting medical device and food and beverage stocks have subsided, with analysts noting a lack of concern at recent conferences. The popularity of GLP-1 drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound continues to grow, but concerns about their long-term impact on industries have eased. Medical device sales have actually surged due to increased interest in continuous glucose monitoring devices, while some pharmaceutical companies, like Sanofi, are not pursuing the trend. Food and beverage stocks, including McDonald's, have rebounded, and restaurant demand remains strong, with factors like side effects and limited insurance coverage for weight loss drugs mitigating potential negative impacts.

via Yahoo Finance|

#businesshealthcare #food-and-beverage-stocks #glp-1s

healthcarepharmaceuticals2 years ago•3 min saved

"Shifting Landscape: The Future of Weight Loss Drugs in 2024"

Prominent weight-loss drugs, known as GLP-1s, made by Novo Nordisk and Eli Lilly, may not have as much lasting impact on healthcare in 2024 as previously expected. Analysts are predicting less need for medtech devices and surgeries due to the popularity of these drugs, but recent commentary suggests a shift away from the initial fear and panic surrounding their impact. Fast-food and fast-casual chains' valuation rebound is credited to a cooling GLP-1 narrative, with industry veterans noting that accessibility to these drugs is difficult for lower-income consumers and that healthier alternatives may boost business. The uptake of these drugs, accessibility, side effects, and production constraints are still key factors in determining their long-term impact.

via Yahoo Finance|

#eli-lilly #glp-1s #healthcare-sector

pharmaceuticals2 years ago•0 min saved

"Promising Results: Eli Lilly's Zepbound and Tirzepatide Revolutionize Obesity Treatment"

Eli Lilly's weight loss drug, Zepbound, has gained significant attention and media coverage since its FDA approval in November. The drug's availability in pharmacies has sparked further interest, fueled by discussions on social media about GLP-1s and off-label use of similar treatments.

via Endpoints News|

#eli-lilly #fda-approval #glp-1s

business2 years ago•6 min saved

The Truth Behind Weight-Loss Drugs: Hype or Hope?

Analyst Andrew Charles of TD Cowen believes that weight-loss drugs like Ozempic or Wegovy, despite being named Novo Nordisk's Company of the Year, will have a limited long-term impact on calorie reduction and overall population health. TD Cowen's outlook for GLP-1s predicts 14.3 million people in the US taking the drugs, resulting in a 30% reduction in calories by users and a 0.07% decrease in overall US population calorie consumption. Charles suggests that stocks like Domino's Pizza, Wingstop, and Darden Restaurants may be more protected from the potential impact of weight-loss drugs due to their focus on delivery and dining out occasions.

via Yahoo Finance|

#business #calorie-reduction #glp-1s